leisure time -WSS

leisure time

author：Wikipedia 2025-10-03 00:07:58 - browse：79

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Surge in Apellis stock fueled by confidence in safety of its eye drug

explore

WSS

Live blog: Hearing on CRISPR

Coloradans with cystic fibrosis could lose access to Trikafta

Schizophrenia gene found to be linked to cells' energy dysfunction

Medicare proceeds with plan to claw back hospital funds

Biogen’s boardroom scandal saddles CEO with first crisis

Travis Kelce and the trap of celebrity vaccine endorsements

explore

leisure time

entertainment

What does generative AI mean for health care? We asked experts

Brain injuries and the importance of a second opinion

In Memoriam: Notable people who died in 2023

Novo Nordisk touts Wegovy study, but still struggling with supply

Sports medicine is finally prioritizing gender equality

BMS, looking to build heart drug business, turns to AI for diagnosis

What does generative AI mean for health care? We asked experts

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Sports medicine is finally prioritizing gender equality

Key Senate panel to consider PBM, drug pricing reform package

Wikipedia

All of Us, NIH's precision medicine initiative, gets a big boost

How to convince healthy people to buy insurance

Surge in Apellis stock fueled by confidence in safety of its eye drug

Novo Nordisk touts Wegovy study, but still struggling with supply

Key Senate panel to consider PBM, drug pricing reform package

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

explore

entertainment

Wikipedia

hotspot